Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Coherus Oncology's Debt-to-EBITDA or its related term are showing as below:
FRA:8C5'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.48 Med: -0.69 Max: 2.61
Current: -0.27
During the past 13 years, the highest Debt-to-EBITDA Ratio of Coherus Oncology was 2.61. The lowest was -2.48. And the median was -0.69.
FRA:8C5's Debt-to-EBITDA is ranked worse than 100% of 296
companies
in the Biotechnology industry
Industry Median: 1.15
vs FRA:8C5: -0.27
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Coherus Oncology Debt-to-EBITDA Related Terms
Coherus Oncology Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8C5 vs NAUT, AVXL, SLNCF: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Coherus Oncology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Coherus Oncology (FRA:8C5) has a Debt-to-EBITDA of -0.33 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Coherus Oncology. According to the industry distribution chart, Coherus Oncology ranks #999999 out of 296 companies in the Biotechnology industry.
Is Coherus Oncology's Debt-to-EBITDA too high?
Coherus Oncology's current Debt-to-EBITDA is -0.33. Based on the distribution chart, Coherus Oncology ranks #999999 out of 296 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Coherus Oncology has a GF Score™ of 42/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Debt-to-EBITDA compare to NAUT and AVXL?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #999999 out of 296 companies for Debt-to-EBITDA. This places Coherus Oncology in the lower half of its industry. The industry median Debt-to-EBITDA is 1.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.15, based on 296 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Coherus Oncology. For the Biotechnology industry, the median Debt-to-EBITDA is 1.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coherus Oncology's current Debt-to-EBITDA is -0.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.88, compared to a current price of €1.06 — trading 20.3% above its estimated fair value. The current Debt-to-EBITDA is -0.33. Coherus Oncology's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current Debt-to-EBITDA is -0.33 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (FRA:8C5) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of €1.06 is trading 20.3% above its estimated GF Value™ of €0.88.
GuruFocus considers Coherus Oncology to be Modestly Overvalued.
Key valuation signals for FRA:8C5:
Debt-to-EBITDA: -0.33
GF Value™: €0.88 vs. price of €1.06 (20.3% above fair value)
No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
42GF Score
Get the complete analysis for FRA:8C5
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8C5 has been successfully added to your 
